Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 11/20 | 0.37 |
| ▸ | CA2 | P00918 | 10/20 | 0.37 |
| ▸ | CA12 | O43570 | 7/20 | 0.37 |
| ▸ | CA9 | Q16790 | 6/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854385 | 0.85 | KDM4E (0.37) | CA1CA2CA12CA9CA7 | |
| SCHEMBL10374343 | 0.84 | PPARG (0.41) | NPFFR1NPFFR2SIGMAR1CA1CA12 | |
| SCHEMBL10365408 | 0.81 | CTSS (0.37) | NPFFR1NPFFR2SIGMAR1 | |
| SCHEMBL10365440 | 0.81 | CNR2 (0.41) | NPFFR1NPFFR2SIGMAR1 | |
| SCHEMBL3311103 | 0.80 | LMNA (0.36) | — | |
| SCHEMBL15771401 | 0.79 | L3MBTL1 (0.45) | — | |
| SCHEMBL15771400 | 0.79 | L3MBTL1 (0.45) | — | |
| SCHEMBL5863065 | 0.76 | CTSK (0.45) | — | |
| SCHEMBL3309119 | 0.73 | CTSS (0.43) | — | |
| SCHEMBL15956594 | 0.72 | LMNA (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198438-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198438-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198438-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100113454-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113454-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113454-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2134716-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008131050-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008131050-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113454-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, LCK, MAP3K15 | NPFFR1 1806/4885NPFFR2 1672/4885SIGMAR1 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.